About

Violetta Hughes was appointed the Company's Chief Accounting Officer, effective September 1, 2025, becoming the Company's principal accounting officer (replacing Jason K. Garland in that capacity, while Mr. Garland continues as CFO). She is a seasoned finance executive with deep expertise in financial controllership, operational finance, and global team leadership across life sciences, medical technology and pharmaceuticals, bringing over 25 years of experience.

From January 2023 to August 2025, Ms. Hughes served as VP and Chief Accounting Officer at Azenta, Inc. (NASDAQ: AZTA). From December 2020 to December 2022, she served as SVP and Chief Accounting Officer at Akebia Therapeutics, Inc. (NASDAQ: AKBA). Prior to AKBA, from December 2016 to November 2020, she served as SVP of Accounting, Corporate Controller at AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), until its acquisition by Covis Pharma in November 2020.

Ms. Hughes holds a B.S. in Accounting from the University of Massachusetts Lowell.

Roles

Repligen Corp.
Chief Accounting Officer · Current role
2025–present
Azenta, Inc. (NASDAQ: AZTA)
VP and Chief Accounting Officer · January 2023 to August 2025; led enterprise-wide initiatives to modernize financial systems, streamline close processes, and improve SOX compliance.
2023-2025
Akebia Therapeutics, Inc. (NASDAQ: AKBA)
SVP and Chief Accounting Officer · December 2020 to December 2022; fully-integrated biopharmaceutical company focusing on kidney diseases.
2020-2022
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
SVP of Accounting, Corporate Controller · December 2016 to November 2020; until its acquisition by Covis Pharma in November 2020.
2016-2020

Also at Repligen Corp.

Related

See how VectorShift works for your firm

Request Demo